Related references
Note: Only part of the references are listed.A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer
H. Raza Ali et al.
JOURNAL OF PATHOLOGY (2012)
Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
Keith D. Amos et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson et al.
BRITISH JOURNAL OF CANCER (2010)
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Sharon Barrans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer
Tarek M. A. Abdel-Fatah et al.
JOURNAL OF PATHOLOGY (2010)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2010)
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
Gunter von Minckwitz et al.
BREAST CANCER RESEARCH (2008)
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
GM Callagy et al.
CLINICAL CANCER RESEARCH (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
